Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 6/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.44 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.43 |
| ▸ | ALB | P02768 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4599294 | 1.00 | FOLH1 (0.49) | FOLH1ITGB3ITGA2BALDH1A1HIF1A | |
| SCHEMBL4599881 | 0.88 | GPR34 (0.54) | ITGB3ITGA2BALDH1A1SMN1; SMN2GPR34 | |
| SCHEMBL4599884 | 0.88 | GPR34 (0.54) | ITGB3ITGA2BALDH1A1SMN1; SMN2GPR34 | |
| SCHEMBL4600549 | 0.88 | GPR34 (0.57) | ITGB3ITGA2BALDH1A1GPR34 | |
| SCHEMBL4600543 | 0.88 | GPR34 (0.57) | ITGB3ITGA2BALDH1A1GPR34 | |
| SCHEMBL4600461 | 0.86 | ALDH1A1 (0.54) | ITGB3ITGA2BALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4600451 | 0.86 | ALDH1A1 (0.54) | ITGB3ITGA2BALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL20637849 | 0.83 | ITGB3 (0.54) | FOLH1ITGB3ITGA2BSLC15A2ALB | |
| SCHEMBL9752048 | 0.83 | KMT2A (0.57) | ITGB3ITGA2BALDH1A1 | |
| SCHEMBL4739869 | 0.80 | GPR34 (0.48) | FOLH1ALDH1A1SMN1; SMN2GPR34 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| WO-2008080223-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-10 | — | — | WO | disclosed |
| EP-1910279-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2008-04-16 | — | — | EP | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| WO-2007002639-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | FOLH1 771/4885ITGB3 1550/4885ITGA2B 2449/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | FOLH1 1486/4885ITGB3 4006/4885ITGA2B 3909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.